The biotech company just reported data from a pair of successful late-stage clinical trials.
News & Analysis: Incyte
Big drug developers reinvest revenues from cash-cow products to fuel the pipeline for the future.
INCY earnings call for the period ending December 31, 2019.
The biotech posted strong sales growth for all three of its approved drugs.
Though the pharmaceutical company reported a big clinical trial failure last month, there are other reasons for optimism.
The drug moves closer to an expanded approval for the skin disorder.
The Food and Drug Administration will expedite its review of capmatinib.
These three stocks have major events coming up this month -- and it's not just the release of earnings that investors will be watching.
A failed study disappointed investors, but the company's pipeline should withstand the blow.
But the biotech won't release details about how well it works until later.